Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months’ treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. The data points to an excellent safety profile and promising signs of clinical activity, with 60% of patients who reached the six-month mark showing improved bone marrow fibrosis scores.
Pharmaxis says majority of patients in fibrosis trial see significant improvement
